;PMID: 11097231
;source_file_726.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..56] = [t:0..56]
;1)sentence:[e:61..204] = [t:61..204]
;2)section:[e:208..338] = [t:208..338]
;3)section:[e:342..486] = [t:342..486]
;4)sentence:[e:490..566] = [t:490..566]
;5)sentence:[e:568..788] = [t:568..788]
;6)sentence:[e:789..1045] = [t:789..1045]
;7)sentence:[e:1046..1153] = [t:1046..1153]
;8)sentence:[e:1154..1378] = [t:1154..1378]
;9)sentence:[e:1379..1491] = [t:1379..1491]
;10)sentence:[e:1492..1622] = [t:1492..1622]
;11)sentence:[e:1623..1764] = [t:1623..1764]
;12)sentence:[e:1765..1939] = [t:1765..1939]
;13)sentence:[e:1940..2017] = [t:1940..2017]
;14)sentence:[e:2018..2138] = [t:2018..2138]
;15)sentence:[e:2139..2315] = [t:2139..2315]
;16)sentence:[e:2316..2422] = [t:2316..2422]
;17)sentence:[e:2423..2744] = [t:2423..2744]
;18)sentence:[e:2745..2942] = [t:2745..2942]
;19)sentence:[e:2943..3053] = [t:2943..3053]
;20)section:[e:3057..3102] = [t:3057..3102]

;section 0 Span:0..56
;Cancer Epidemiol Biomarkers Prev  2000 Nov;9(11):1223-32
(SEC
  (FRAG (NNP:[0..6] Cancer) (NNP:[7..16] Epidemiol) (NNP:[17..27] Biomarkers)
        (NNP:[28..32] Prev) (CD:[34..38] 2000) (.:[39..45] Nov;9-LRB-)
        (CD:[45..47] 11) (-RRB-:[47..48] -RRB-) (CD:[48..53] :1223)
        (::[53..54] -) (CD:[54..56] 32)))

;sentence 1 Span:61..204
;K-ras and p53 in pancreatic cancer: association with medical history, 
;histopathology, and environmental exposures in a population-based study.
;[61..66]:gene-rna:"K-ras"
;[71..74]:gene-rna:"p53"
;[78..95]:malignancy:"pancreatic cancer"
(SENT
  (NP-HLN
    (NP
      (NP (NN:[61..66] K-ras) (CC:[67..70] and) (NN:[71..74] p53))
      (PP (IN:[75..77] in)
        (NP (JJ:[78..88] pancreatic) (NN:[89..95] cancer))))
    (::[95..96] :)
    (NP
      (NP (NN:[97..108] association))
      (PP (IN:[109..113] with)
        (NP
          (NP (JJ:[114..121] medical) (NN:[122..129] history))
          (,:[129..130] ,)
          (NP (NN:[132..146] histopathology))
          (,:[146..147] ,) (CC:[148..151] and)
          (NP (JJ:[152..165] environmental) (NNS:[166..175] exposures))))
      (PP (IN:[176..178] in)
        (NP (DT:[179..180] a)
          (ADJP (NN:[181..191] population) (HYPH:[191..192] -)
                (VBN:[192..197] based))
          (NN:[198..203] study))))
    (.:[203..204] .)))

;section 2 Span:208..338
;Slebos RJ, Hoppin JA, Tolbert PE, Holly EA, Brock JW, Zhang RH, Bracci PM,
;Foley  J, Stockton P, McGregor LM, Flake GP, Taylor JA.
(SEC
  (FRAG (NNP:[208..214] Slebos) (NNP:[215..217] RJ) (,:[217..218] ,)
        (NNP:[219..225] Hoppin) (NNP:[226..228] JA) (,:[228..229] ,)
        (NNP:[230..237] Tolbert) (NNP:[238..240] PE) (,:[240..241] ,)
        (NNP:[242..247] Holly) (NNP:[248..250] EA) (,:[250..251] ,)
        (NNP:[252..257] Brock) (NNP:[258..260] JW) (,:[260..261] ,)
        (NNP:[262..267] Zhang) (NNP:[268..270] RH) (,:[270..271] ,)
        (NNP:[272..278] Bracci) (NNP:[279..281] PM) (,:[281..282] ,)
        (NNP:[283..288] Foley) (NNP:[290..292] J,) (NNP:[293..301] Stockton)
        (NNP:[302..303] P) (,:[303..304] ,) (NNP:[305..313] McGregor)
        (NNP:[314..316] LM) (,:[316..317] ,) (NNP:[318..323] Flake)
        (NNP:[324..326] GP) (,:[326..327] ,) (NNP:[328..334] Taylor)
        (.:[335..338] JA.)))

;section 3 Span:342..486
;Laboratory of Molecular Carcinogenesis, National Institute of Environmental 
;Health Sciences, Research Triangle Park, North Carolina 27709, USA.
(SEC
  (FRAG (NN:[342..352] Laboratory) (IN:[353..355] of) (NNP:[356..365] Molecular)
        (NNP:[366..380] Carcinogenesis) (,:[380..381] ,)
        (NNP:[382..390] National) (NNP:[391..400] Institute) (IN:[401..403] of)
        (NNP:[404..417] Environmental) (NNP:[419..425] Health)
        (NNP:[426..434] Sciences) (,:[434..435] ,) (NNP:[436..444] Research)
        (NNP:[445..453] Triangle) (NNP:[454..458] Park) (,:[458..459] ,)
        (NNP:[460..465] North) (NNP:[466..474] Carolina) (CD:[475..480] 27709)
        (,:[480..481] ,) (NNP:[482..485] USA) (.:[485..486] .)))

;sentence 4 Span:490..566
;Pancreatic cancer is a highly fatal cancer with few identified risk factors.
;[490..507]:malignancy:"Pancreatic cancer"
(SENT
  (S
    (NP-SBJ (JJ:[490..500] Pancreatic) (NN:[501..507] cancer))
    (VP (VBZ:[508..510] is)
      (NP-PRD
        (NP (DT:[511..512] a)
          (ADJP (RB:[513..519] highly) (JJ:[520..525] fatal))
          (NN:[526..532] cancer))
        (PP (IN:[533..537] with)
          (NP (JJ:[538..541] few) (VBN:[542..552] identified)
              (NN:[553..557] risk) (NNS:[558..565] factors)))))
    (.:[565..566] .)))

;sentence 5 Span:568..788
;Increased risk of pancreatic cancer in tobacco smokers and among diabetic 
;patients is well established, and some reports have suggested associations
;with  coffee consumption and occupational exposure to organochlorines.
;[586..603]:malignancy:"pancreatic cancer"
(SENT
  (S
    (S
      (NP-SBJ
        (NP
          (NP (VBN:[568..577] Increased) (NN:[578..582] risk))
          (PP (IN:[583..585] of)
            (NP (JJ:[586..596] pancreatic) (NN:[597..603] cancer))))
        (PP
          (PP (IN:[604..606] in)
            (NP (NN:[607..614] tobacco) (NNS:[615..622] smokers)))
          (CC:[623..626] and)
          (PP (IN:[627..632] among)
            (NP (JJ:[633..641] diabetic) (NNS:[643..651] patients)))))
      (VP (VBZ:[652..654] is)
        (ADJP-PRD (RB:[655..659] well) (VBN:[660..671] established))))
    (,:[671..672] ,) (CC:[673..676] and)
    (S
      (NP-SBJ (DT:[677..681] some) (NNS:[682..689] reports))
      (VP (VBP:[690..694] have)
        (VP (VBN:[695..704] suggested)
          (NP
            (NP (NNS:[705..717] associations))
            (PP (IN:[718..722] with)
              (NP
                (NP (NN:[724..730] coffee) (NN:[731..742] consumption))
                (CC:[743..746] and)
                (NP
                  (NP (JJ:[747..759] occupational) (NN:[760..768] exposure))
                  (PP (TO:[769..771] to)
                    (NP (NNS:[772..787] organochlorines))))))))))
    (.:[787..788] .)))

;sentence 6 Span:789..1045
;At present,  there is little information regarding the possible association
;of these risk  factors with the known genetic alterations found in pancreatic
;cancers, such as  activation of the K-ras oncogene and inactivation of the
;p53 tumor suppressor  gene.
;[932..950]:malignancy:"pancreatic cancers"
;[979..984]:gene-rna:"K-ras"
;[1018..1021]:gene-rna:"p53"
(SENT
  (S
    (PP-TMP (IN:[789..791] At)
      (NP (NN:[792..799] present)))
    (,:[799..800] ,)
    (NP-SBJ (EX:[802..807] there))
    (VP (VBZ:[808..810] is)
      (NP-PRD
        (NP (JJ:[811..817] little) (NN:[818..829] information))
        (PP (VBG:[830..839] regarding)
          (NP
            (NP (DT:[840..843] the) (JJ:[844..852] possible)
                (NN:[853..864] association))
            (PP (IN:[865..867] of)
              (NP (DT:[868..873] these) (NN:[874..878] risk)
                  (NNS:[880..887] factors)))
            (PP (IN:[888..892] with)
              (NP
                (NP
                  (NP (DT:[893..896] the) (VBN:[897..902] known)
                      (JJ:[903..910] genetic) (NNS:[911..922] alterations))
                  (VP (VBN:[923..928] found)
                    (NP (-NONE-:[928..928] *))
                    (PP-LOC (IN:[929..931] in)
                      (NP (JJ:[932..942] pancreatic) (NNS:[943..950] cancers)))))
                (,:[950..951] ,)
                (PP (JJ:[952..956] such) (IN:[957..959] as)
                  (NP
                    (NP
                      (NP (NN:[961..971] activation))
                      (PP (IN:[972..974] of)
                        (NP (DT:[975..978] the) (NN:[979..984] K-ras)
                            (NN:[985..993] oncogene))))
                    (CC:[994..997] and)
                    (NP
                      (NP (NN:[998..1010] inactivation))
                      (PP (IN:[1011..1013] of)
                        (NP (DT:[1014..1017] the) (NN:[1018..1021] p53)
                          (NML (NN:[1022..1027] tumor)
                               (NN:[1028..1038] suppressor))
                          (NN:[1040..1044] gene))))))))))))
    (.:[1044..1045] .)))

;sentence 7 Span:1046..1153
;Knowledge of such relationships may help to understand the molecular 
;pathways of pancreatic tumorigenesis.
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1046..1055] Knowledge))
      (PP (IN:[1056..1058] of)
        (NP (JJ:[1059..1063] such) (NNS:[1064..1077] relationships))))
    (VP (MD:[1078..1081] may)
      (VP (VB:[1082..1086] help)
        (S
          (NP-SBJ (-NONE-:[1086..1086] *))
          (VP (TO:[1087..1089] to)
            (VP (VB:[1090..1100] understand)
              (NP
                (NP (DT:[1101..1104] the) (JJ:[1105..1114] molecular)
                    (NNS:[1116..1124] pathways))
                (PP (IN:[1125..1127] of)
                  (NP (JJ:[1128..1138] pancreatic)
                      (NN:[1139..1152] tumorigenesis)))))))))
    (.:[1152..1153] .)))

;sentence 8 Span:1154..1378
;We investigated the association between  these molecular defects and risk
;factors for pancreatic cancer in 61 newly  diagnosed patients identified
;through an ongoing study of pancreatic cancer in  the San Francisco Bay
;Area.
;[1240..1257]:malignancy:"pancreatic cancer"
;[1329..1346]:malignancy:"pancreatic cancer"
(SENT
  (S
    (NP-SBJ (PRP:[1154..1156] We))
    (VP (VBD:[1157..1169] investigated)
      (NP
        (NP (DT:[1170..1173] the) (NN:[1174..1185] association))
        (PP (IN:[1186..1193] between)
          (NP
            (NP (DT:[1195..1200] these) (JJ:[1201..1210] molecular)
                (NNS:[1211..1218] defects))
            (CC:[1219..1222] and)
            (NP
              (NP (NN:[1223..1227] risk) (NNS:[1228..1235] factors))
              (PP (IN:[1236..1239] for)
                (NP (JJ:[1240..1250] pancreatic) (NN:[1251..1257] cancer)))))))
      (PP-LOC (IN:[1258..1260] in)
        (NP
          (NP (CD:[1261..1263] 61)
            (ADJP (RB:[1264..1269] newly) (VBN:[1271..1280] diagnosed))
            (NNS:[1281..1289] patients))
          (VP (VBN:[1290..1300] identified)
            (NP (-NONE-:[1300..1300] *))
            (PP (IN:[1301..1308] through)
              (NP
                (NP (DT:[1309..1311] an) (JJ:[1312..1319] ongoing)
                    (NN:[1320..1325] study))
                (PP (IN:[1326..1328] of)
                  (NP (JJ:[1329..1339] pancreatic) (NN:[1340..1346] cancer)))
                (PP-LOC (IN:[1347..1349] in)
                  (NP (DT:[1351..1354] the)
                    (NML (NNP:[1355..1358] San) (NNP:[1359..1368] Francisco))
                    (NNP:[1369..1372] Bay) (NNP:[1373..1377] Area)))))))))
    (.:[1377..1378] .)))

;sentence 9 Span:1379..1491
;Interview information was obtained regarding  environmental exposures,
;medical history, and demographic factors.
(SENT
  (S
    (NP-SBJ-1 (NN:[1379..1388] Interview) (NN:[1389..1400] information))
    (VP (VBD:[1401..1404] was)
      (VP (VBN:[1405..1413] obtained)
        (NP-1 (-NONE-:[1413..1413] *))
        (PP (VBG:[1414..1423] regarding)
          (NP
            (NP (JJ:[1425..1438] environmental) (NNS:[1439..1448] exposures))
            (,:[1448..1449] ,)
            (NP (JJ:[1450..1457] medical) (NN:[1458..1465] history))
            (,:[1465..1466] ,) (CC:[1467..1470] and)
            (NP (JJ:[1471..1482] demographic) (NNS:[1483..1490] factors))))))
    (.:[1490..1491] .)))

;sentence 10 Span:1492..1622
;Serum levels  of dichlorodiphenyltrichloroethylene (DDE) and polychlorinated
;biphenyls were  available on a subset of 24 patients.
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1492..1497] Serum) (NNS:[1498..1504] levels))
      (PP (IN:[1506..1508] of)
        (NP
          (NP
            (NP (NN:[1509..1542] dichlorodiphenyltrichloroethylene))
            (NP (-LRB-:[1543..1544] -LRB-) (NN:[1544..1547] DDE)
                (-RRB-:[1547..1548] -RRB-)))
          (CC:[1549..1552] and)
          (NP (VBN:[1553..1568] polychlorinated) (NNS:[1569..1578] biphenyls)))))
    (VP (VBD:[1579..1583] were)
      (ADJP-PRD (JJ:[1585..1594] available)
        (PP (IN:[1595..1597] on)
          (NP
            (NP (DT:[1598..1599] a) (NN:[1600..1606] subset))
            (PP (IN:[1607..1609] of)
              (NP (CD:[1610..1612] 24) (NNS:[1613..1621] patients)))))))
    (.:[1621..1622] .)))

;sentence 11 Span:1623..1764
;Tumor blocks were located from local  hospitals and used for K-ras mutational
;analysis at codon 12 and for p53 protein  immunohistochemistry.
;[1684..1689]:gene-rna:"K-ras"
;[1713..1721]:variation-location:"codon 12"
;[1730..1733]:gene-protein:"p53"
(SENT
  (S
    (NP-SBJ-1 (NN:[1623..1628] Tumor) (NNS:[1629..1635] blocks))
    (VP (VBD:[1636..1640] were)
      (VP
        (VP (VBN:[1641..1648] located)
          (NP-1 (-NONE-:[1648..1648] *))
          (PP (IN:[1649..1653] from)
            (NP (JJ:[1654..1659] local) (NNS:[1661..1670] hospitals))))
        (CC:[1671..1674] and)
        (VP (VBN:[1675..1679] used)
          (NP-1 (-NONE-:[1679..1679] *))
          (PP
            (PP (IN:[1680..1683] for)
              (NP
                (NP (NN:[1684..1689] K-ras) (JJ:[1690..1700] mutational)
                    (NN:[1701..1709] analysis))
                (PP-LOC (IN:[1710..1712] at)
                  (NP (NN:[1713..1718] codon) (CD:[1719..1721] 12)))))
            (CC:[1722..1725] and)
            (PP (IN:[1726..1729] for)
              (NP (NN:[1730..1733] p53) (NN:[1734..1741] protein)
                  (NN:[1743..1763] immunohistochemistry)))))))
    (.:[1763..1764] .)))

;sentence 12 Span:1765..1939
;The molecular analyses were facilitated through the use of  laser capture
;microdissection, which provides a reliable method to obtain almost  pure
;populations of tumor cells.
(SENT
  (S
    (NP-SBJ-2 (DT:[1765..1768] The) (JJ:[1769..1778] molecular)
              (NNS:[1779..1787] analyses))
    (VP (VBD:[1788..1792] were)
      (VP (VBN:[1793..1804] facilitated)
        (NP-2 (-NONE-:[1804..1804] *))
        (PP (IN:[1805..1812] through)
          (NP
            (NP (DT:[1813..1816] the) (NN:[1817..1820] use))
            (PP (IN:[1821..1823] of)
              (NP
                (NP (NN:[1825..1830] laser) (NN:[1831..1838] capture)
                    (NN:[1839..1854] microdissection))
                (,:[1854..1855] ,)
                (SBAR
                  (WHNP-1 (WDT:[1856..1861] which))
                  (S
                    (NP-SBJ-1 (-NONE-:[1861..1861] *T*))
                    (VP (VBZ:[1862..1870] provides)
                      (NP
                        (NP (DT:[1871..1872] a) (JJ:[1873..1881] reliable)
                            (NN:[1882..1888] method))
                        (SBAR
                          (WHNP-3 (-NONE-:[1888..1888] 0))
                          (S
                            (NP-SBJ-3 (-NONE-:[1888..1888] *T*))
                            (VP (TO:[1889..1891] to)
                              (VP (VB:[1892..1898] obtain)
                                (NP
                                  (NP
                                    (ADJP (RB:[1899..1905] almost)
                                          (JJ:[1907..1911] pure))
                                    (NNS:[1912..1923] populations))
                                  (PP (IN:[1924..1926] of)
                                    (NP (NN:[1927..1932] tumor)
                                        (NNS:[1933..1938] cells))))))))))))))))))
    (.:[1938..1939] .)))

;sentence 13 Span:1940..2017
;Mutations in K-ras codon 12 were found in 46  (75%) of 61 pancreatic
;cancers.
;[1940..1949]:variation-event:"Mutations"
;[1953..1958]:gene-rna:"K-ras"
;[1959..1967]:variation-location:"codon 12"
;[1998..2016]:malignancy:"pancreatic cancers"
(SENT
  (S
    (NP-SBJ-1
      (NP (NNS:[1940..1949] Mutations))
      (PP-LOC (IN:[1950..1952] in)
        (NP (NN:[1953..1958] K-ras)
           (NN:[1959..1964] codon) (CD:[1965..1967] 12))))
    (VP (VBD:[1968..1972] were)
      (VP (VBN:[1973..1978] found)
        (NP-1 (-NONE-:[1978..1978] *))
        (PP-LOC (IN:[1979..1981] in)
          (NP
            (NP (CD:[1982..1984] 46)
              (PRN (-LRB-:[1986..1987] -LRB-)
                (NP (CD:[1987..1989] 75) (NN:[1989..1990] %))
                (-RRB-:[1990..1991] -RRB-)))
            (PP (IN:[1992..1994] of)
              (NP (CD:[1995..1997] 61)
                 (JJ:[1998..2008] pancreatic) (NNS:[2009..2016] cancers)))))))
    (.:[2016..2017] .)))

;sentence 14 Span:2018..2138
;A prior diagnosis of diabetes was significantly  associated with K-ras
;negative tumors (P = 0.002, Fisher's exact test).
;[2083..2104]:malignancy:"K-ras negative tumors"
;[2083..2088]:gene-rna:"K-ras"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[2018..2019] A) (JJ:[2020..2025] prior)
          (NN:[2026..2035] diagnosis))
      (PP (IN:[2036..2038] of)
        (NP (NN:[2039..2047] diabetes))))
    (VP (VBD:[2048..2051] was)
      (ADVP (RB:[2052..2065] significantly))
      (VP (VBN:[2067..2077] associated)
        (NP-1 (-NONE-:[2077..2077] *))
        (PP-CLR (IN:[2078..2082] with)
          (NP
            (ADJP (NN:[2083..2088] K-ras) (JJ:[2089..2097] negative))
            (NNS:[2098..2104] tumors)))
        (PRN (-LRB-:[2105..2106] -LRB-)
          (FRAG
            (S
              (NP-SBJ (NN:[2106..2107] P))
              (VP (SYM:[2108..2109] =)
                (NP (CD:[2110..2115] 0.002))))
            (,:[2115..2116] ,)
            (NP
              (NP (NNP:[2117..2123] Fisher) (POS:[2123..2125] 's))
              (JJ:[2126..2131] exact) (NN:[2132..2136] test)))
          (-RRB-:[2136..2137] -RRB-))))
    (.:[2137..2138] .)))

;sentence 15 Span:2139..2315
;The  absence of this mutation was also associated with increased serum levels
;of DDE,  although this association was not statistically significant (P =
;0.16,  Wilcoxon's test).
;[2160..2168]:variation-event:"mutation"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[2139..2142] The) (NN:[2144..2151] absence))
      (PP (IN:[2152..2154] of)
        (NP (DT:[2155..2159] this) (NN:[2160..2168] mutation))))
    (VP (VBD:[2169..2172] was)
      (ADVP (RB:[2173..2177] also))
      (VP (VBN:[2178..2188] associated)
        (NP-1 (-NONE-:[2188..2188] *))
        (PP-CLR (IN:[2189..2193] with)
          (NP
            (NP (VBN:[2194..2203] increased) (NN:[2204..2209] serum)
                (NNS:[2210..2216] levels))
            (PP (IN:[2217..2219] of)
              (NP (NN:[2220..2223] DDE)))))
        (,:[2223..2224] ,)
        (SBAR-ADV (IN:[2226..2234] although)
          (S
            (NP-SBJ (DT:[2235..2239] this) (NN:[2240..2251] association))
            (VP (VBD:[2252..2255] was) (RB:[2256..2259] not)
              (ADJP-PRD (RB:[2260..2273] statistically)
                        (JJ:[2274..2285] significant)
                (PRN (-LRB-:[2286..2287] -LRB-)
                  (FRAG
                    (S
                      (NP-SBJ (NN:[2287..2288] P))
                      (VP (SYM:[2289..2290] =)
                        (NP (CD:[2291..2295] 0.16))))
                    (,:[2295..2296] ,)
                    (NP
                      (NP (NNP:[2298..2306] Wilcoxon) (POS:[2306..2308] 's))
                      (NN:[2309..2313] test)))
                  (-RRB-:[2313..2314] -RRB-))))))))
    (.:[2314..2315] .)))

;sentence 16 Span:2316..2422
;There was no difference in polychlorinated biphenyl levels  between the K-ras
;wild-type and mutant groups.
;[2388..2393]:gene-rna:"K-ras"
(SENT
  (S
    (NP-SBJ (EX:[2316..2321] There))
    (VP (VBD:[2322..2325] was)
      (NP-PRD
        (NP (DT:[2326..2328] no) (NN:[2329..2339] difference))
        (PP (IN:[2340..2342] in)
          (NP (VBN:[2343..2358] polychlorinated) (NN:[2359..2367] biphenyl)
              (NNS:[2368..2374] levels)))
        (PP (IN:[2376..2383] between)
          (NP (DT:[2384..2387] the)
            (NML
              (NML (NN:[2388..2393] K-ras)
                (NML (JJ:[2394..2398] wild) (HYPH:[2398..2399] -)
                     (NN:[2399..2403] type))
                (NML-1 (-NONE-:[2403..2403] *P*)))
              (CC:[2404..2407] and)
              (NML (JJ:[2408..2414] mutant)
                (NML-1 (NNS:[2415..2421] groups))))))))
    (.:[2421..2422] .)))

;sentence 17 Span:2423..2744
;Immunohistochemical staining for  p53 protein did not differ by patient
;characteristics or clinical history, but  significant associations were found
;with poor glandular differentiation (P =  0.002, chi2 trend test), severe
;nuclear atypia (P = 0.0007, chi2 trend test),  and high tumor grade (P =
;0.004, chi2 trend test).
;[2457..2460]:gene-protein:"p53"
;[2640..2661]:malignancy:"severe nuclear atypia"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (JJ:[2423..2442] Immunohistochemical) (NN:[2443..2451] staining))
        (PP (IN:[2452..2455] for)
          (NP (NN:[2457..2460] p53) (NN:[2461..2468] protein))))
      (VP (VBD:[2469..2472] did) (RB:[2473..2476] not)
        (VP (VB:[2477..2483] differ)
          (PP (IN:[2484..2486] by)
            (NP
              (NP (NN:[2487..2494] patient) (NNS:[2495..2510] characteristics))
              (CC:[2511..2513] or)
              (NP (JJ:[2514..2522] clinical) (NN:[2523..2530] history)))))))
    (,:[2530..2531] ,) (CC:[2532..2535] but)
    (S
      (NP-SBJ-2
        (NP (JJ:[2537..2548] significant) (NNS:[2549..2561] associations))
        (PP-1 (-NONE-:[2561..2561] *ICH*)))
      (VP (VBD:[2562..2566] were)
        (VP (VBN:[2567..2572] found)
          (NP-2 (-NONE-:[2572..2572] *))
          (PP-1 (IN:[2573..2577] with)
            (NP
              (NP (JJ:[2578..2582] poor) (JJ:[2583..2592] glandular)
                  (NN:[2593..2608] differentiation)
                (PRN (-LRB-:[2609..2610] -LRB-)
                  (FRAG
                    (S
                      (NP-SBJ (NN:[2610..2611] P))
                      (VP (SYM:[2612..2613] =)
                        (NP (CD:[2615..2620] 0.002))))
                    (,:[2620..2621] ,)
                    (NP (NN:[2622..2626] chi2) (NN:[2627..2632] trend)
                        (NN:[2633..2637] test)))
                  (-RRB-:[2637..2638] -RRB-)))
              (,:[2638..2639] ,)
              (NP
                 (JJ:[2640..2646] severe) (JJ:[2647..2654] nuclear)
                 (NN:[2655..2661] atypia)
                (PRN (-LRB-:[2662..2663] -LRB-)
                  (FRAG
                    (S
                      (NP-SBJ (NN:[2663..2664] P))
                      (VP (SYM:[2665..2666] =)
                        (NP (CD:[2667..2673] 0.0007))))
                    (,:[2673..2674] ,)
                    (NP (NN:[2675..2679] chi2) (NN:[2680..2685] trend)
                        (NN:[2686..2690] test)))
                  (-RRB-:[2690..2691] -RRB-)))
              (,:[2691..2692] ,) (CC:[2694..2697] and)
              (NP (JJ:[2698..2702] high) (NN:[2703..2708] tumor)
                  (NN:[2709..2714] grade)
                (PRN (-LRB-:[2715..2716] -LRB-)
                  (FRAG
                    (S
                      (NP-SBJ (NN:[2716..2717] P))
                      (VP (SYM:[2718..2719] =)
                        (NP (CD:[2720..2725] 0.004))))
                    (,:[2725..2726] ,)
                    (NP (NN:[2727..2731] chi2) (NN:[2732..2737] trend)
                        (NN:[2738..2742] test)))
                  (-RRB-:[2742..2743] -RRB-))))))))
    (.:[2743..2744] .)))

;sentence 18 Span:2745..2942
;Our results are suggestive of  the presence of K-ras codon 12
;mutation-independent tumorigenesis pathways in  patients with prior diabetes
;and possibly in patients with higher serum levels  of DDE.
;[2792..2797]:gene-rna:"K-ras"
;[2798..2806]:variation-location:"codon 12"
;[2807..2815]:variation-event:"mutation"
(SENT
  (S
    (NP-SBJ (PRP$:[2745..2748] Our) (NNS:[2749..2756] results))
    (VP (VBP:[2757..2760] are)
      (ADJP-PRD (JJ:[2761..2771] suggestive)
        (PP (IN:[2772..2774] of)
          (NP
            (NP (DT:[2776..2779] the) (NN:[2780..2788] presence))
            (PP (IN:[2789..2791] of)
              (NP
                (ADJP
                  (NML (NN:[2792..2797] K-ras)
                    (NML (NN:[2798..2803] codon) (CD:[2804..2806] 12))
                    (NN:[2807..2815] mutation))
                  (HYPH:[2815..2816] -) (JJ:[2816..2827] independent))
                (NN:[2828..2841] tumorigenesis) (NNS:[2842..2850] pathways)))
            (PP-LOC
              (PP (IN:[2851..2853] in)
                (NP
                  (NP (NNS:[2855..2863] patients))
                  (PP (IN:[2864..2868] with)
                    (NP (JJ:[2869..2874] prior) (NN:[2875..2883] diabetes)))))
              (CC:[2884..2887] and)
              (PP
                (ADVP (RB:[2888..2896] possibly))
                (IN:[2897..2899] in)
                (NP (NNS:[2900..2908] patients)
                  (PP (IN:[2909..2913] with)
                    (NP
                      (NP (JJR:[2914..2920] higher) (NN:[2921..2926] serum)
                          (NNS:[2927..2933] levels))
                      (PP (IN:[2935..2937] of)
                        (NP (NN:[2938..2941] DDE))))))))))))
    (.:[2941..2942] .)))

;sentence 19 Span:2943..3053
;Our results also support a role for the p53 tumor suppressor protein in  the
;maintenance of genomic integrity.
;[2983..2986]:gene-protein:"p53"
(SENT
  (S
    (NP-SBJ (PRP$:[2943..2946] Our) (NNS:[2947..2954] results))
    (ADVP (RB:[2955..2959] also))
    (VP (VBP:[2960..2967] support)
      (NP (DT:[2968..2969] a) (NN:[2970..2974] role))
      (PP (IN:[2975..2978] for)
        (NP (DT:[2979..2982] the) (NN:[2983..2986] p53)
          (NML (NN:[2987..2992] tumor) (NN:[2993..3003] suppressor))
          (NN:[3004..3011] protein)))
      (PP (IN:[3012..3014] in)
        (NP
          (NP (DT:[3016..3019] the) (NN:[3020..3031] maintenance))
          (PP (IN:[3032..3034] of)
            (NP (JJ:[3035..3042] genomic) (NN:[3043..3052] integrity))))))
    (.:[3052..3053] .)))

;section 20 Span:3057..3102
;PMID: 11097231 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[3057..3061] PMID) (::[3061..3062] :) (CD:[3063..3071] 11097231)
        (NN:[3072..3073] -LSB-) (NNP:[3073..3079] PubMed) (::[3080..3081] -)
        (NN:[3082..3089] indexed) (IN:[3090..3093] for)
        (NNP:[3094..3102] MEDLINE-RSB-)))
